Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice

Raouia Fakhfakh, Se Jin Lee, Jacques P. Tremblay

Research output: Contribution to journalArticle

Abstract

Duchenne muscular dystrophy (DMD) is a recessive disease caused by a dystrophin gene mutation. Myoblast transplantation permits the introduction of the dystrophin gene into dystrophic muscle fibers. However, this strategy has so far produced limited results. Modulation of transforming growth factor-β (TGF-β) superfamily signaling promotes skeletal muscle differentiation and growth and myogenic regeneration. We investigated the possibility that the combination of TGF-β superfamily signaling inhibition with myoblast transplantation might be an effective therapeutic approach in dystrophin-deficient patients. In vitro, blocking myostatin and other ligands with a soluble form of the extracellular domain of the activin IIB receptor (ActRIIB/Fc) upregulated the expression of myogenic differentiation factors and increased human myoblast fusion. In vivo, systemic inhibition of activin IIB receptor signaling by delivery of ActRIIB/Fc increased the success of the myoblast transplantation. This effect was further increased by forcing the mice to swim weekly to induce cycles of muscle degeneration and regeneration. Treatment of dystrophic mice with ActRIIB/Fc led to increased body weight, increased skeletal muscle mass, and improved myoblast transplantation. Thus, ActRIIB/Fc represents an effective therapeutic strategy for muscular dystrophies, and its effects are enhanced when combined with muscle exercise.

Original languageEnglish (US)
Pages (from-to)1419-1430
Number of pages12
JournalCell Transplantation
Volume21
Issue number7
DOIs
StatePublished - 2012

Fingerprint

Myoblasts
Muscle
Transplantation
Dystrophin
Transforming Growth Factors
Muscles
Regeneration
Skeletal Muscle
Genes
Myostatin
Duchenne Muscular Dystrophy
Muscular Dystrophies
Fusion reactions
Therapeutics
Ligands
Body Weight
Modulation
activin receptor type II-B
Exercise
Mutation

Keywords

  • Activin receptor
  • Duchenne muscular dystrophy (DMD)
  • Myoblast transplantation
  • Transforming growth factor- and beta; (TGF- and beta;) superfamily

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice. / Fakhfakh, Raouia; Lee, Se Jin; Tremblay, Jacques P.

In: Cell Transplantation, Vol. 21, No. 7, 2012, p. 1419-1430.

Research output: Contribution to journalArticle

Fakhfakh, Raouia ; Lee, Se Jin ; Tremblay, Jacques P. / Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice. In: Cell Transplantation. 2012 ; Vol. 21, No. 7. pp. 1419-1430.
@article{a1a584da28024e3096a7ea0a7f535997,
title = "Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice",
abstract = "Duchenne muscular dystrophy (DMD) is a recessive disease caused by a dystrophin gene mutation. Myoblast transplantation permits the introduction of the dystrophin gene into dystrophic muscle fibers. However, this strategy has so far produced limited results. Modulation of transforming growth factor-β (TGF-β) superfamily signaling promotes skeletal muscle differentiation and growth and myogenic regeneration. We investigated the possibility that the combination of TGF-β superfamily signaling inhibition with myoblast transplantation might be an effective therapeutic approach in dystrophin-deficient patients. In vitro, blocking myostatin and other ligands with a soluble form of the extracellular domain of the activin IIB receptor (ActRIIB/Fc) upregulated the expression of myogenic differentiation factors and increased human myoblast fusion. In vivo, systemic inhibition of activin IIB receptor signaling by delivery of ActRIIB/Fc increased the success of the myoblast transplantation. This effect was further increased by forcing the mice to swim weekly to induce cycles of muscle degeneration and regeneration. Treatment of dystrophic mice with ActRIIB/Fc led to increased body weight, increased skeletal muscle mass, and improved myoblast transplantation. Thus, ActRIIB/Fc represents an effective therapeutic strategy for muscular dystrophies, and its effects are enhanced when combined with muscle exercise.",
keywords = "Activin receptor, Duchenne muscular dystrophy (DMD), Myoblast transplantation, Transforming growth factor- and beta; (TGF- and beta;) superfamily",
author = "Raouia Fakhfakh and Lee, {Se Jin} and Tremblay, {Jacques P.}",
year = "2012",
doi = "10.3727/096368911X627480",
language = "English (US)",
volume = "21",
pages = "1419--1430",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "7",

}

TY - JOUR

T1 - Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice

AU - Fakhfakh, Raouia

AU - Lee, Se Jin

AU - Tremblay, Jacques P.

PY - 2012

Y1 - 2012

N2 - Duchenne muscular dystrophy (DMD) is a recessive disease caused by a dystrophin gene mutation. Myoblast transplantation permits the introduction of the dystrophin gene into dystrophic muscle fibers. However, this strategy has so far produced limited results. Modulation of transforming growth factor-β (TGF-β) superfamily signaling promotes skeletal muscle differentiation and growth and myogenic regeneration. We investigated the possibility that the combination of TGF-β superfamily signaling inhibition with myoblast transplantation might be an effective therapeutic approach in dystrophin-deficient patients. In vitro, blocking myostatin and other ligands with a soluble form of the extracellular domain of the activin IIB receptor (ActRIIB/Fc) upregulated the expression of myogenic differentiation factors and increased human myoblast fusion. In vivo, systemic inhibition of activin IIB receptor signaling by delivery of ActRIIB/Fc increased the success of the myoblast transplantation. This effect was further increased by forcing the mice to swim weekly to induce cycles of muscle degeneration and regeneration. Treatment of dystrophic mice with ActRIIB/Fc led to increased body weight, increased skeletal muscle mass, and improved myoblast transplantation. Thus, ActRIIB/Fc represents an effective therapeutic strategy for muscular dystrophies, and its effects are enhanced when combined with muscle exercise.

AB - Duchenne muscular dystrophy (DMD) is a recessive disease caused by a dystrophin gene mutation. Myoblast transplantation permits the introduction of the dystrophin gene into dystrophic muscle fibers. However, this strategy has so far produced limited results. Modulation of transforming growth factor-β (TGF-β) superfamily signaling promotes skeletal muscle differentiation and growth and myogenic regeneration. We investigated the possibility that the combination of TGF-β superfamily signaling inhibition with myoblast transplantation might be an effective therapeutic approach in dystrophin-deficient patients. In vitro, blocking myostatin and other ligands with a soluble form of the extracellular domain of the activin IIB receptor (ActRIIB/Fc) upregulated the expression of myogenic differentiation factors and increased human myoblast fusion. In vivo, systemic inhibition of activin IIB receptor signaling by delivery of ActRIIB/Fc increased the success of the myoblast transplantation. This effect was further increased by forcing the mice to swim weekly to induce cycles of muscle degeneration and regeneration. Treatment of dystrophic mice with ActRIIB/Fc led to increased body weight, increased skeletal muscle mass, and improved myoblast transplantation. Thus, ActRIIB/Fc represents an effective therapeutic strategy for muscular dystrophies, and its effects are enhanced when combined with muscle exercise.

KW - Activin receptor

KW - Duchenne muscular dystrophy (DMD)

KW - Myoblast transplantation

KW - Transforming growth factor- and beta; (TGF- and beta;) superfamily

UR - http://www.scopus.com/inward/record.url?scp=84868519883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868519883&partnerID=8YFLogxK

U2 - 10.3727/096368911X627480

DO - 10.3727/096368911X627480

M3 - Article

C2 - 22449443

AN - SCOPUS:84868519883

VL - 21

SP - 1419

EP - 1430

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 7

ER -